Research programme: benzopyrane derivatives - Nissan Chemical
Alternative Names: NIP-151Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Nissan Chemical Industries
- Class Benzopyrans
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atrial fibrillation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atrial-fibrillation in Japan
- 01 Feb 2008 The programme is still in active development
- 20 Dec 2005 Data presented at the 78th Scientific Sessions of the American Heart Association (AHA-2005) have been added to the Arrhythmia pharmacodynamics section